close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Castle Biosciences, Inc.

< Previous 1 2 3 4 5 6 Next >
News headline image
New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical Procedure
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx®-Melanoma at the College of American Pathologists 2022 (CAP22) Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx®-Melanoma and Clinicopathologic Factors Provides Optimized, Personalized Survival Prognoses for Patients with Cutaneous Melanoma
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests at Maui Derm NP+PA Fall 2022 Conference
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Presents Foundational Guideposts and Three-Year Financial Targets at 2022 Investor Day
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Honored with a 2022 AZBio Fast Lane Award from the Arizona Bioindustry Association
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Host Investor Day on Sept. 20, 2022
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Reports Second Quarter 2022 Results
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
American Gastroenterological Association (AGA) Clinical Practice Update States That TissueCypher® May Be Beneficial for Risk-Stratification of Patients with Non-Dysplastic Barrett’s Esophagus
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth Conference
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
DecisionDx®-Melanoma Ordered More Than 100,000 Times for Patients Diagnosed with Cutaneous Melanoma
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Presentation at 2022 AAD Innovation Academy to Showcase the Risk Stratification of DecisionDx®-Melanoma and its Role in the Management of Patients with Cutaneous Melanoma
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Honored with a 2022 Arizona Top Workplace Award
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Patients with Uveal Melanoma Tested with DecisionDx®-UM Report Gaining Value from Test Results In Study Conducted In Collaboration with the Melanoma Research Foundation’s CURE OM Initiative
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Announces Support for OHSU’s War on Melanoma™
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Collaborative Study with Melanoma Research Foundation Confirms Patients Diagnosed with Melanoma Desire Testing with DecisionDx®-Melanoma
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Present at the JMP Securities Life Sciences Conference
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences’ DecisionDx®-Melanoma Test Receives 2022 MedTech Breakthrough Award
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Data Demonstrating DecisionDx®-Melanoma’s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
TissueCypher® Outperforms Pathologist Diagnoses When Predicting Progression in Patients Diagnosed with Barrett’s Esophagus with Low-Grade Dysplasia
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Reports First Quarter 2022 Results
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Camille Schrier, Miss America 2020, and Castle Biosciences Partner to Expand Awareness of Genetic Testing in Depression and Anxiety
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today